Navigation Links
Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
Date:10/10/2009

PHOENIX and SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona. NKTR-118, an oral peripherally-acting opioid antagonist, is a late stage investigational product candidate in clinical development for the treatment of opioid-induced constipation. NKTR-118 was developed by Nektar, utilizing its proprietary small molecule advanced polymer conjugate technology platform.

Today's presentation at AAPM includes topline data previously announced by the company in March 2009. In a Phase 2 double-blind, randomized, placebo-controlled study of 208 patients with opioid-induced constipation, NKTR-118 met the primary endpoint of increase in spontaneous bowel movements over the baseline period. There was no reversal or reduction of opioid-mediated analgesia in any dose groups. NKTR-118 was also well tolerated with the most commonly reported side effects being dose-dependent gastrointestinal-related effects.

Download Today's Poster Presentation for NKTR-118

The poster presentation from today's AAPM 20th Annual Clinical Meeting can be found on Nektar's website at http://www.nektar.com/product_pipeline/cns_pain_oral_nktr-118and119.html

AAPM Poster #39: "NKTR-118 Significantly Reverses Opioid-Induced Constipation"

Complete Data from NKTR-118 Phase 2 Clinical Trial to be presented in Oral Plenary Session at ACG 2009

Data from the Phase 2 clinical trial of NKTR-118 have been accepted for presentation in an oral plenary session of the American College of Gastroenterology (ACG
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
2. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
3. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
6. Biotel Announces Fourth Quarter and Year End Results
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
9. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
10. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... ... of Business Development, Asia Pacific. In this newly-created position, Gibbs will lead iLab’s ... use of iLab’s suite of tools. This entails not only introducing iLab to ...
(Date:8/31/2015)... Milpitas, Calif. (PRWEB) , ... August 31, 2015 ... ... earlier this year to bring together supply chain risk management and resiliency practitioners ... collaborate, develop and share best practices, and be recognized for their innovations and ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Mexico Biomedical Sensors Market - Growth, Trends & ... The Mexico Biomedical Sensors market is estimated ... 2.68% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/31/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... review period following the filing of the Company,s ... the U.S. Food and Drug Administration (FDA) has ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Biology Technology:iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4
... , - German Chemical Parks ... The number of employees in German chemical parks ... In this same period, the number of,companies doing business at ... today by Dr. Klaus-Dieter Juszak, Chairman of the,German Sector Group ...
... EXPANSION INTO EUROPE AND STRENGTHENS ITS SENIOR MANAGEMENT ... 12 OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), ... for clinical trials, today announced that it has strengthened ... of Dr. Wolfgang Summa. As Executive Vice President, Europe ...
... today that it has acquired from biotechnology company Antisoma ... film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) ... United States for use as a second-line therapy to ... pleased to add Oforta to our existing oncology portfolio, ...
Cached Biology Technology:10,000 New Jobs, Investments Increased 210,000 New Jobs, Investments Increased 3OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 2OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 3Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 2Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 3
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Vitamin and mineral supplements can enhance mental energy and ... prone to anxiety and depression, according to a July ... Technologists (IFT) Annual Meeting & Food Expo held at ... faculty of medicine at the University of Calgary, Alberta, ...
... size and parental behavior are the key drivers in children,s ... the 2013 Institute of Food Technologists (IFT) Annual Meeting & ... crowd of more than 200 conference attendees heard new insights ... eating behaviors are and how the industry and parents can ...
... (OGL), New England Biolabs, Inc., and Northeastern University have reached ... tissue from the world,s most rare, strange, and remarkable ocean ... Ocean Genome Legacy , Founded in 2001 ... New England Biolabs, OGL is a non-profit environmental research organization ...
Cached Biology News:Taste rules for kids and healthy food choices 2Collection that may hold key to ocean's mysteries looks to expand in new waterfront home 2
... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... on one plate. The new ArraySlide 96 ... (7mm x 7mm) individual printing surfaces for ... analysis studies. Unlike other systems, this device ... presence of contaminating adhesives. The chamber itself ...
... chambers for sealing hybridization reactions on slides. The ... on a glass slide. Reaction solution is added ... are then sealed with plastic sealing dots. Dots ... of reaction fluid. These chambers enclose a 20 ...
Biology Products: